Quantcast

Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR

May 16, 2011

SAN DIEGO, May 16, 2011 /PRNewswire/ — Volcano Corporation (NASDAQ: VOLC) today announced its participation in the Paris course for Revascularization (EuroPCR) from May 17 – 20. Volcano’s focus will be on highlighting the strength of its product portfolio, which includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® RX), and its sponsorship of a symposium that highlights the use and value of Precision Guided Therapy in clinical practice today.

“Volcano is excited to share our state-of-the-art intravascular therapy guidance and optimization solutions at this year’s EuroPCR,” commented Scott Huennekens, President and CEO of Volcano. “Globally, clinicians are pleased about the insight our technologies provide them so they can more precisely personalize the treatment of their patients.”

Scientific Symposium on Precision Guided Therapy

Volcano is sponsoring a symposium designed to provide real world experiences and novel techniques from key opinion leaders in interventional cardiology from France, Poland, Italy, and the UK. “Precision Guided Therapy: Simple techniques to go beyond angiography in everyday practice” will take place on Wednesday, May 18th, in Room 352AB in the Palais Des Congres.

Product Innovations

Volcano will feature its suite of precision guided therapy technologies, which includes integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. These products, which are all available for sale in the U.S. and/or Europe, include:

  • The PrimeWire PRESTIGE(TM), the next generation Fractional Flow Reserve (FFR) wire with a familiar frontline tip, better torque and more support for challenging lesions;
  • The Eagle Eye® Platinum, the #1 digital IVUS catheter in the world, which provides exceptional deliverability, the convenience of radiopaque markers, and three imaging modalities including grayscale IVUS, VH® IVUS and ChromaFlo®;
  • The VIBE® RX Vascular Imaging Balloon Catheter, which can quickly access, prepare, and assess challenging lesions and provide precise, targeted balloon dilatation with immediate confirmation of interventional results; and
  • The s5(TM)/s5i(TM) 3.2.1 software, which streamlines the workflow for both IVUS and FFR procedures and is compatible with more than 3,700 Volcano systems installed worldwide.

Volcano plans to highlight progress in the development of a prototype allowing the co-registration of IVUS images with angiography in an automated fashion. This technology has the potential to disburden clinicians from identifying the relationship between the angiographic image and the IVUS information on non-registered data sets. “We are confident that the combination of two existing imaging modalities will ease the workflow for the physician during coronary interventions,” continued Huennekens.

All products will be available for demonstration at Booth #F29, Level 1. Volcano’s technology will also be on display in other booths, including GE Healthcare, Siemens Healthcare, Philips Healthcare, and Toshiba Medical Systems. In addition, Volcano will highlight its extensive pipeline of imaging and therapy products still in development, including Optical Coherence Tomography (OCT), Micro Catheters, and Forward Looking Imaging.

Live Case Transmissions

Throughout EuroPCR, Volcano technology, including FFR, IVUS, Image-Guided Therapy, and Image Co-Registration, will be featured in live case transmissions from around the world.

About Volcano Corporation

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information – using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause Volcano’s results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company’s products and technologies, growth strategies, timing and achievement of regulatory approvals, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market developments, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano’s filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation


Source: newswire



comments powered by Disqus